Adverse effect · Amycretin

How common is trial retention with Amycretin?

C
Grade C — weak human evidence1 phase 1b/2a RCT · effect size: moderate · adverse
Short answerWeak human evidence. 1 phase 1b/2a RCT: enough to be interesting, not enough to count on. Where an effect is seen it is a moderate effect. The trial reports a high withdrawal rate. Because dropouts were largely for reasons unrelated to adverse events, the remaining participants may not represent everyone who started — the standard caution for an early-phase efficacy figure.

What the studies show

The trial reports a high withdrawal rate. Because dropouts were largely for reasons unrelated to adverse events, the remaining participants may not represent everyone who started — the standard caution for an early-phase efficacy figure.

“A large number of participants withdrew from the study, with a high proportion of discontinuations occurring due to reasons unrelated to treatment-emergent adverse events.”

Verbatim, from the abstractDahl K, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet, 2025;406:149–162

A few small or poorly-controlled human studies. Enough to be interesting; not enough to count on. Most of what gets called “clinically proven” online lives here.

  1. 1

In context

Amycretin is a single molecule that activates both the GLP-1 and the amylin receptor, combining the two mechanisms that CagriSema delivers as two drugs. Its international name is now zenagamtide. In the first published trial — a phase 1b/2a study in 125 people — the highest dose produced 24.3% weight loss at 36 weeks: the largest figure reported for any weight-loss drug at this stage, from a small, early trial in which many participants withdrew. Two phase 2 trials in type 2 diabetes, published in The Lancet in 2026, add a dose-dependent HbA1c reduction of up to 1.7 points; the weight-loss figure has not yet been repeated in a larger trial.

Amycretin is investigational (early phase). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Amycretin proven to cause trial retention?
No. The human evidence is weak (1 phase 1b/2a RCT); LYO grades it C.
What studies are behind the grade?
The trial reports a high withdrawal rate. Because dropouts were largely for reasons unrelated to adverse events, the remaining participants may not represent everyone who started — the standard caution for an early-phase efficacy figure.
Is Amycretin approved for this?
No. Amycretin is investigational (early phase); it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for Amycretin

Written and maintained by LYO Research — how pages are written and checked. Reviewed 23 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →